Measuring What Matters: How Sequential’s Microbiome Testing and AI Are Rewriting Skincare R&D

Key Highlights
Introduction
Why the skin microbiome is the next frontier for effective skincare
What Sequential’s platform measures and how it differs from conventional testing
The dataset advantage: scale, diversity, and coverage
AI-powered discovery: from correlation to prediction
Commercial traction: customers, investors, and the business model
From data to product: how brands will use microbiome-host insights
A hypothetical case: bringing a microbiome-friendly moisturizer to market
Scientific and technical challenges that remain
Regulatory and market acceptance: what counts as evidence?
Data ownership, privacy, and ethical considerations
Competitive landscape and adjacent players
Opportunities beyond consumer skincare: pharma and biotech applications
Limits of current technology and the path to clinical-grade evidence
Business risks and commercialization hurdles
What this means for consumers and brands
Future outlook: where microbiome-informed skincare is headed
FAQ

Key Highlights

Sequential raised $3.5M Seed to scale a proprietary, non-invasive testing platform that quantifies how ingredients and products affect both the skin microbiome and host biomarkers, powering evidence-based product development.
The company’s dataset—50,000+ samples, 4,000+ ingredients, and 10,000+ participants—combined with an AI discovery engine, enables brands to predict and optimize novel bioactives and substantiate efficacy claims.
Sequential serves 100+ paying customers, including Johnson & Johnson, positioning itself as a B2B science partner for consumer skincare, biotech and pharmaceutical companies seeking rigorous, actionable measurements.

Introduction

Skincare has long been governed by promises, fads, and iterative reformulation. Advertising and influencer trends create demand, but the underlying science often lags. Brands test products on panels, run short-term consumer trials, and publish before-and-after photos, yet objective, reproducible measures of how a product alters the skin’s biology remain scarce.

Sequential is changing that calculus. The startup applies a proprietary, non-invasive testing platform to quantify effects on the skin microbiome and host biomarkers, turning qualitative claims into measurable outcomes. Backed by a $3.5 million Seed round led by Sparkfood and Corundum Systems Biology (CSB), and supported by investors including SOSV, Dermazone Holdings, Scrum Ventures, and Innovate UK, Sequential positions itself at the intersection of dermatology, microbiology, and machine learning. The company’s value rests on two pillars: an extensive clinical dataset and an AI-driven discovery engine that predicts which active complexes will shift microbiome composition and host biology in desirable ways.

This article explains why measurement matters for skincare, how Sequential’s approach differs from conventional testing, what a large microbiome-host dataset enables for machine learning, and how this model reshapes product development, regulation, and consumer expectations.

Why the skin microbiome is the next frontier for effective skincare

Skin is an organ and an ecosystem. Trillions of microorganisms—bacteria, fungi, viruses—inhabit distinct skin environments such as oily, dry, and sebaceous zones. These microbes participate in barrier function, immune modulation, and metabolite production that influence skin appearance and health. Shifts in microbial communities correlate with conditions like acne, atopic dermatitis, and rosacea. They also respond to topical ingredients, preservatives, and formulations.

Brands historically focused on visible outcomes—hydration, smoothing, wrinkle reduction—and biochemical proxies like transepidermal water loss. Those metrics remain useful, but they do not reveal how products interact with the living ecosystem on the skin surface or with the host’s molecular responses. Without such insight, ingredient combinations that appear effective in vitro or in small panels may fail in broader, more diverse populations, or worse, cause long-term dysbiosis that undermines skin health.

Measuring microbiome changes alongside host biomarkers — proteins, lipids, inflammatory mediators — captures both sides of the interaction. This dual readout distinguishes transient surface effects from meaningful biological modulation. For product developers, those readouts guide formulation choices, help select synergistic ingredient complexes, and support claims that withstand scientific scrutiny.

What Sequential’s platform measures and how it differs from conventional testing

Sequential’s core offering is a proprietary, non-invasive platform that quantifies shifts in the skin microbiome and host biomarkers after exposure to ingredients or finished products. The platform is designed to be broadly applicable across consumer skincare, biotech programs, and pharmaceutical trials that touch skin biology.

How this differs from typical industry practice:

Traditional consumer trials emphasize subjective perception and basic clinical scoring. Sequential provides molecular and microbial endpoints that are objective and reproducible.
Laboratory assays frequently test ingredients in isolation or in cell culture. Sequential’s platform evaluates ingredients and formulations in situ—on human skin—capturing real-world interactions with resident microbes and host tissue.
Claims validation often relies on small panels and short timelines. Sequential’s dataset and repeated measures allow detection of consistent trends across populations and timepoints.

The platform is non-invasive, lowering participant burden and enabling larger, repeated-sampling studies. Non-invasive sampling streamlines recruitment and reduces attrition, making it feasible to assemble datasets that support robust statistical and machine-learning analyses.

Typical non-invasive sampling approaches used across the field include skin swabs, tape-stripping, sebum collection, and surface rinses. These methods capture microbial DNA, host RNA or protein fragments, metabolites, and lipids. While Sequential’s exact sampling protocols and analytic pipelines are proprietary, their approach integrates microbial sequencing with host biomarker assays to produce a composite view of product impact.

The dataset advantage: scale, diversity, and coverage

Data fuels modern biological discovery. Sequential’s clinical footprint—more than 50,000 samples covering 4,000+ ingredients and 10,000+ participants—delivers three critical advantages for brands and for machine learning systems.

Statistical power Large sample sizes reduce noise inherent in human studies. The microbiome exhibits person-to-person variability influenced by genetics, age, geography, lifestyle, and environmental exposure. With tens of thousands of samples, Sequential can detect subtle but reproducible effects of an ingredient or formula across diverse subpopulations. This mitigates the risk of false positives and supports stratified analyses—for example, evaluating efficacy separately in oily vs. dry skin, or across age brackets.
Ingredient coverage and combinatorial insights Cataloguing data for more than 4,000 ingredients creates opportunity to model ingredient interactions. Many formulations succeed not because of one “active” but because of complexes that modulate absorption, stability, or microbial interactions. Combinatorial datasets allow machine learning to identify synergies and antagonisms among ingredients—insights that are costly and slow to obtain through classic factorial experiments.
Representative participant base Ten thousand participants across multiple geographies reduce demographic bias. Many early-stage dermatology or beauty studies recruit narrow cohorts—young, urban, predominantly one ethnicity. A broader cohort reveals population-specific responses that inform product positioning and claims in different markets.

For brands, dataset scale translates into faster go/no-go decisions. Instead of multiple incremental trials, teams can test candidate actives against historical controls and identify promising hits for focused clinical validation.

AI-powered discovery: from correlation to prediction

Sequential is developing an AI discovery engine intended to predict, discover, and optimize next-generation active complexes and novel bioactive ingredients. The engine leverages the company's sizeable paired microbiome-host dataset to build predictive models that connect ingredient inputs to biological outcomes.

What predictive modeling enables:

Virtual screening of large chemical and botanical libraries to prioritize candidates before committing to wet-lab testing.
Optimization of multi-ingredient complexes to maximize desired microbiome shifts while minimizing inflammatory responses.
Identification of biomarkers that serve as early surrogate endpoints for long-term benefits, shortening development cycles.

AI approaches likely in play include supervised learning for outcome prediction, unsupervised methods for clustering response phenotypes, and causal inference techniques to probe likely mechanistic relationships between ingredients and biological endpoints. Advanced models can incorporate temporal dynamics, modeling how the microbiome and host biomarkers evolve over repeated exposures.

Practical outcomes for brands:

Reduced R&D costs. Predictive models narrow the experimental space, translating to fewer human trials and faster formulation cycles.
More defensible claims. Products informed by predictive science can point to model-based evidence supported by prospective validation.
Proprietary actives and IP. Engine-derived complexes that show robust predicted benefits can be developed into exclusive ingredients or licensed.

AI in life sciences succeeds when models train on high-quality, relevant data. Sequential’s dataset is tailored to the use case—human skin exposures—making the transition from in-silico hypothesis to validated product more feasible than general-purpose chemical libraries alone.

Commercial traction: customers, investors, and the business model

Sequential’s commercial runway is anchored by more than 100 paying customers, including a major consumer healthcare firm, Johnson & Johnson. Corporate partnerships matter in this sector: established brands bring scale, regulatory experience, and distribution channels; startups bring agility and focused scientific capability.

Investor composition underscores confidence in Sequential’s approach. The $3.5M Seed round—co-led by Sparkfood and Corundum Systems Biology, with participation from SOSV, Dermazone Holdings, Scrum Ventures, and Innovate UK—signals appetite for platform companies that sit between consumer packaged goods (CPG) and biotech. These investors have backgrounds in food science, life sciences infrastructure, and enterprise R&D, reflecting the cross-disciplinary nature of microbiome-driven product innovation.

Sequential’s likely revenue streams:

B2B service contracts for product testing and biomarker analysis.
Subscription or licensing of analytics dashboards and model outputs.
Collaborative discovery partnerships with co-development milestones and royalties for novel actives.
Data and insight reports for market positioning and claims support.

Brands with internal R&D teams may contract Sequential for specific validation projects. Companies lacking in-house biology expertise can outsource entire discovery pipelines. For pharmaceutical and biotech companies working on topical therapeutics, Sequential’s platform offers an additional readout to conventional clinical endpoints—helpful when the microbiome intersects with drug efficacy or safety.

From data to product: how brands will use microbiome-host insights

Brands confront several decisions during product development: which active to test, how to formulate it, how to position claims, and how to design clinical endpoints. Measured microbiome-host data influences each step.

Ingredient selection and prioritization Instead of relying on literature and supplier claims alone, developers can test ingredients across cohorts to quantify their impact on key microbial taxa and host biomarkers. An ingredient that increases beneficial commensal species and reduces pro-inflammatory markers becomes a higher-priority candidate.
Formulation optimization Microbes respond to excipients, pH, emulsifiers, and preservatives. A formulation scientist can use Sequential’s readouts to iterate on vehicle and concentration, aiming to preserve or restore a healthy microbiome while delivering efficacy.
Claims substantiation Regulatory agencies and consumers demand evidence. Objective microbiome and biomarker changes, when paired with clinical outcomes, form a rigorous foundation for claims like “supports skin barrier function” or “reduces markers of inflammation.” Brands can publish peer-reviewed data or create substantiation dossiers for regulatory review.
Personalization and segmentation Not all skin is created equal. Brands can use stratified response data to design personalized regimens—formulations or routines tailored to microbial profiles or biomarker patterns. Personalization increases perceived value and can command premium pricing.
Post-market surveillance After launch, products can be monitored in real-world use to ensure microbiome stability and detect rare adverse responses. Continuous monitoring protects brand reputation and informs iterative improvements.

These use cases create a feedback loop: data from post-market surveillance enriches the training dataset, improving future predictions and product iterations.

A hypothetical case: bringing a microbiome-friendly moisturizer to market

A mid-size skincare brand aims to launch a “microbiome-friendly” moisturizer. The traditional path involves in-vitro testing, a small clinical panel for hydration and tolerability, and consumer perception trials. Using Sequential’s platform, the brand follows a different path:

Discovery The brand submits a shortlist of candidate actives. The AI engine screens a broader chemical space and suggests a novel peptide-botanical complex predicted to increase Cutibacterium acnes commensal strains associated with reduced inflammation, while enhancing ceramide synthesis markers in host assays.
Preclinical human study A 200-participant panel across three geographies undergoes non-invasive sampling at baseline, one week, and four weeks. Sequential measures microbiome taxonomic shifts and host biomarkers linked to barrier function and inflammation.
Optimization Data reveals that the peptide complex performs best at a particular pH and in a glycerin-rich vehicle. The brand reformulates accordingly.
Validation A larger 800-person randomized study confirms measurable increases in beneficial taxa, reduced pro-inflammatory biomarker signature, improved hydration metrics, and superior subjective ratings.
Launch and claims Armed with objective data, the brand markets the moisturizer as “clinically shown to support beneficial skin microbes and markers of barrier health,” and includes de-identified study results online and in regulatory dossiers.
Post-market The brand offers an optional at-home test kit for consumers to monitor microbiome trends, feeding anonymized data back to Sequential for ongoing learning.

This workflow reduces the number of failed experiments, strengthens claims, and differentiates the product in a crowded market.

Scientific and technical challenges that remain

Scaling microbiome-host testing into routine R&D faces technical and biological challenges.

Biological variability and confounders Human skin varies with season, environment, hygiene habits, and topical product history. Distinguishing true ingredient effects from confounding variables demands careful study design, adequate washout periods, and robust controls.

Sampling consistency Non-invasive sampling methods must balance participant comfort with data quality. Factors such as pressure during tape-stripping, swab area, or swab rotation can influence yields. Standardized protocols and operator training are essential.

Sequencing and analytic limits Microbial sequencing choices matter. 16S rRNA amplicon sequencing provides taxonomic snapshots but lacks strain-level resolution and functional inference. Shotgun metagenomics increases resolution but is costlier. Host biomarker assays range from targeted cytokine panels to high-throughput proteomics and transcriptomics, each with trade-offs in cost, sensitivity, and interpretability.

Causality versus correlation Observational shifts in microbial taxa and biomarkers do not automatically indicate causality. Determining whether a microbial change drives clinical benefit—or is a byproduct of another mechanism—requires complementary experiments, including mechanistic in vitro or animal studies in some cases.

Regulatory acceptance Regulators evaluate claims based on clinical relevance and reproducibility. Microbiome endpoints are novel and may not substitute for established clinical outcomes. Industry and regulators will need to co-develop guidance on acceptable biomarker endpoints for claims or labeling.

Ethical and privacy considerations Microbiome data derives from human participants and, when combined with host biomarkers or metadata, can be sensitive. Companies must ensure informed consent, robust de-identification, and secure data governance. Cross-border data transfer introduces compliance complexity with laws like GDPR.

Sequential’s platform must address these challenges through rigorous standard operating procedures, transparent analytic pipelines, and external validation to win broad industry trust.

Regulatory and market acceptance: what counts as evidence?

Marketing claims for skincare sit in a patchwork regulatory environment. Claims that imply disease treatment trigger pharmaceutical regulation, while cosmetic claims fall under less stringent consumer product rules in many jurisdictions. Nonetheless, regulatory bodies and retailers increasingly demand objective substantiation.

Evidence types that strengthen claims:

Randomized, controlled trials with clinically relevant endpoints.
Objective molecular endpoints correlated with clinical benefit.
Reproducible results across independent cohorts and geographies.
Peer-reviewed publications or third-party validations.

Microbiome endpoints are gaining legitimacy, especially when changes in microbial communities correlate with clinically meaningful host biomarker shifts. For example, a persistent reduction in biomarkers tied to inflammation, paired with favorable microbial shifts, provides stronger support for a claim than microbiome change alone.

Retailers and trade organizations are raising standards. Large buyers and premium channels will prefer partners who can deliver rigorous data. For brands, early investment in robust measurement avoids costly recalls, reputational risk, and regulatory pushback.

Data ownership, privacy, and ethical considerations

Large-scale human-derived datasets carry responsibilities. Companies working with participant samples must meet ethical standards.

Key considerations:

Consent scope: Participants must understand how their data and samples will be used, including for model training, potential commercial discovery, and anonymized data sharing.
Anonymization and re-identification risk: Microbiome profiles can be unique. Governance should apply state-of-the-art de-identification and restrict re-identification attempts.
Data access controls: Limit internal and external access based on need and implement audit trails.
Compensation and benefit-sharing: Participants and communities might expect transparency about commercial uses of aggregate data and, in some cases, benefit-sharing mechanisms.
Cross-border legal compliance: Exporting biological information across jurisdictions requires legal review and appropriate safeguards.

Sequential’s commercial model must transparently communicate policies and integrate ethical oversight to maintain participant trust and enable corporate customers to comply with their own governance requirements.

Competitive landscape and adjacent players

The emergence of microbiome-informed products has attracted startups, academic groups, and established CPG companies. Providers range from consumer-facing microbiome testing firms to service labs offering sequencing and analysis. Sequential’s differentiation lies in combining a proprietary paired microbiome-host dataset with an AI discovery engine and a B2B service orientation.

Adjacent players include:

Sequencing and analytics platforms that offer raw data services to researchers and brands.
Ingredient suppliers developing microbiome-targeted actives.
Contract research organizations (CROs) focusing on dermatology trials.
Consumer microbiome testing companies that supply personalized reports but typically lack paired host biomarker data.

Sequential’s placement—clinical-scale sampling plus predictive modeling—addresses a gap between basic sequencing services and full-scale product discovery. Its success depends on maintaining high-quality data pipelines, expanding dataset diversity, and delivering predictive outputs that translate into validated products.

Opportunities beyond consumer skincare: pharma and biotech applications

The skin microbiome intersects with multiple medical conditions and therapeutic strategies. Sequential’s platform has applications beyond cosmetics.

Therapeutic development Topical therapeutics for conditions like atopic dermatitis, acne, chronic wounds, and graft-versus-host disease interact with the skin microbiome. Measuring microbiome-host dynamics can illuminate mechanisms of action, identify biomarkers of response, and support early-phase trials.

Drug safety Some systemic drugs cause dermatologic side effects. Monitoring the microbiome and skin biomarkers in drug trials can detect adverse responses earlier and help mitigate safety risks.

Biologics and microbe-based therapies Emerging classes of therapies aim to modulate the skin microbiome directly—live biotherapeutic products or small molecules targeting microbial pathways. Sequencing and host assays provide endpoints to evaluate colonization, persistence, and downstream host effects.

Companion diagnostics Predictive models could identify which patients are likely to benefit from a topical treatment based on their baseline microbiome and biomarker profile. Companion diagnostics improve trial design and accelerate regulatory approval by enriching responder populations.

Pharma adoption requires rigorous validation and regulatory alignment, but the underlying scientific rationale is strong: integrating microbiome-host data reduces uncertainty in development and targets interventions more precisely.

Limits of current technology and the path to clinical-grade evidence

While the promise is high, technological and scientific limitations remain.

Strain-level identification Functional differences often reside at the strain level. Current common sequencing approaches may misidentify strain-specific functions. Advancing to strain-resolved metagenomics or complementary culture-based methods increases insight but also costs.
Functional readouts Taxonomic shifts are proxies. Functional profiling—metatranscriptomics, metabolomics, proteomics—captures active processes and metabolites mediating host effects. Integrating multi-omics delivers richer models but demands more sophisticated analytics and higher per-sample expense.
Long-term effects Short-term microbiome changes can differ from long-term outcomes. Longitudinal studies spanning months or years are necessary to ensure interventions produce durable, beneficial effects without unintended dysbiosis.
Interoperability and standards Lack of field-wide standards for sample handling, sequencing, and data reporting hampers cross-study comparability. Field-wide adoption of standards would accelerate validation and regulatory acceptance.

Addressing these limits requires investment in multi-omics workflows, longer trials, and industry-wide collaboration around standards—efforts that Sequential’s investors and partners are well placed to support.

Business risks and commercialization hurdles

Companies operating at the intersection of consumer and life sciences face blended risks.

Cost structure: High-throughput sequencing, host biomarker assays, and clinical panels carry per-sample costs that must be managed to deliver scalable services at reasonable price points for clientele across startup and enterprise segments.
Client adoption: Large incumbents move slowly. Sequential needs to show predictable returns on R&D investment to win long-term partnerships.
Competitive entry: Established lab networks or large pharma R&D units could develop similar capabilities in-house.
Regulatory shifts: Evolving guidance around microbiome claims or human-derived data governance could increase compliance costs or narrow allowable claims.
IP strategy: Protecting algorithmic and dataset-driven insights is challenging; competitors may attempt to replicate capabilities with alternative data sources.

Sequential’s strategic response involves building defensible datasets, cultivating enterprise partnerships, and demonstrating fast ROI through signed collaborations and case studies that illustrate time and cost savings.

What this means for consumers and brands

For consumers, measurement-driven products promise clearer value and fewer empty claims. Instead of committing to trends, shoppers can look for brands that show objective biological effects and transparent study results. Personalized regimens based on their skin’s microbial and molecular profile could yield better outcomes with less trial-and-error.

For brands, the ability to measure the skin’s microbial response and host biomarkers becomes a competitive differentiator. Evidence-backed formulations reduce the risk of wasted launches and can justify premium positioning. Large brands will invest in in-house capabilities or long-term partnerships with platforms like Sequential to secure a steady pipeline of validated innovations.

Retailers and regulators will benefit too. Retailers can reduce returns and consumer complaints by stocking products with stronger evidence. Regulators will gain tools to evaluate consumer safety and substantiation claims more rigorously.

Future outlook: where microbiome-informed skincare is headed

Several trends will shape the next five years:

Greater integration of multi-omics in routine testing, improving functional understanding of ingredient effects.
Emergence of proprietary, validated ingredient complexes created via AI discovery engines and commercialized as licensed actives.
Standardization and partial regulatory recognition of microbiome-host biomarkers as meaningful endpoints for certain claims.
Expansion of personalization services, with optional at-home sampling feeding anonymized data into corporate models.
Increased M&A activity as larger CPG or biotech firms acquire platform players to accelerate in-house capabilities.

The companies that synthesize rigorous human data with predictive modeling will lead the next wave of product innovation, shifting the industry toward measurable, reproducible, and personalized outcomes.

FAQ

Q: What exactly does Sequential measure on the skin? A: Sequential measures changes in the skin microbiome—taxonomic and likely functional shifts—and host biomarkers, which include molecular signals such as proteins, lipids, and inflammatory mediators. The platform uses non-invasive sampling to capture paired data that links microbial community changes with host biological responses.

Q: How is non-invasive sampling advantageous? A: Non-invasive methods reduce participant burden, simplify logistics, and enable repeated sampling across timepoints. This increases study retention and scalability compared with invasive biopsies, while still delivering actionable molecular and microbial data.

Q: Can microbiome changes alone support product claims? A: Microbiome shifts are informative but are stronger when correlated with host biomarkers or clinical outcomes. Regulators and scientific reviewers look for evidence that microbial changes translate into meaningful benefits for skin health or symptom improvement.

Q: How do AI and machine learning fit into the discovery process? A: AI models trained on large paired datasets predict which ingredients or complexes are likely to produce desired microbiome-host outcomes. This prioritizes candidates for physical testing, reduces experimental burden, and helps design optimized formulations.

Q: What safeguards protect participant privacy and data? A: Studies must implement informed consent, de-identification protocols, secure data storage, and access controls. Ethical governance should outline data uses, including commercial applications, and comply with legal frameworks like GDPR when applicable.

Q: How reliable are microbiome measurements given person-to-person variability? A: Reliable results require adequate sample sizes, standardized sampling protocols, and appropriate statistical models. Large, diverse datasets help distinguish signal from noise and enable stratified analyses that account for population-level variability.

Q: How quickly can brands expect results from Sequential’s testing? A: Turnaround depends on study design, cohort size, and assay complexity. Small targeted tests can return insights in weeks; larger validation studies span months. The AI engine can accelerate candidate prioritization prior to human testing.

Q: Will this approach reduce the time and cost of R&D? A: Predictive modeling and large-scale baseline data reduce the experimental search space, which can lower costs and shorten timelines. However, rigorous human validation remains essential for regulatory compliance and consumer trust.

Q: Can these methods be applied to medical skin conditions? A: Yes. The same principles—paired microbiome and host biomarker measurement—apply to therapeutic development and safety monitoring in dermatology. Clinical-grade validation and regulatory alignment are required for therapeutic claims.

Q: How should brands communicate microbiome-related claims to consumers? A: Transparency and clarity matter. Brands should present measurable endpoints, study conditions, and limitations in plain language. Claims should avoid implying disease treatment and should align with regulatory definitions for cosmetics versus drugs.

Q: Who benefits from this shift toward measurement-driven skincare? A: Consumers benefit from clearer evidence and potentially more effective, personalized products. Brands gain more efficient R&D and stronger differentiation. The scientific community gains richer datasets to understand skin ecology and host interactions.

Q: What are the main barriers to widespread adoption? A: Key barriers include per-sample costs, the need for standardization, regulatory uncertainty around microbiome endpoints, and operational complexity of integrating multi-omics data into product pipelines.

Q: How does Sequential differentiate from other microbiome testing companies? A: Sequential pairs microbiome sequencing with host biomarker assays at scale and is building an AI discovery engine trained specifically on paired human-skin exposure data. The company focuses on B2B services for product development and claims substantiation rather than consumer-facing home reports.

Q: What should brands ask when evaluating a microbiome testing partner? A: Ask about sample size requirements, standardization of protocols, types of host biomarkers measured, data governance practices, availability of predictive analytics, validation examples, and long-term data stewardship and access.

Q: Can consumers test their own skin microbiome to guide product choices? A: Consumer tests exist, but they typically provide taxonomic summaries without paired host biomarker data or AI-driven product optimization. Consumer-level results may offer general insights but are less actionable than clinical-grade, paired analyses for product development.

Q: How will this shift change the beauty industry? A: The industry will move toward evidence-based differentiation. Brands that invest in measurable outcomes will outcompete those relying on marketing alone. Product claims will become more scientific, and personalization will become a standard premium feature.

Q: Where can brands and researchers find more information about Sequence-style studies? A: Look for peer-reviewed literature on skin microbiome studies that include host biomarker readouts, industry white papers, and conference proceedings in dermatology and cosmetic science. Engaging directly with service providers for pilot projects is the fastest route to practical insight.